"This Fast Track designation is a significant milestone for Cothera Bioscience and reflects the potential of PC-002 targeting Myc driven cancers," said Alex Wu, Ph.D., CEO of Cothera Bioscience. "We ...

Liver cancer is the third-leading cause of cancer-related deaths worldwide, and the disease is often diagnosed at an advanced stage when there are significantly limited treatment options.

Researchers at Fred Hutchinson Cancer Center, led by Dr. Julie McElrath, Director of the Vaccine and Infectious Disease Division, have found a new way to train our immune system to make antibodies ...

Deciding on antigen vs. antibody tests when choosing a COVID-19 test is easier when the definitions and their function are clear. These tests represent different ways you can check for SARS-CoV-2, the ...

This cancer is driven by the presence of a gene called MYC which triggers rapid disease growth and often results in treatment failure. By bringing together the largest cohort of MYC amplified ...

The research has the potential to be a valuable addition to the field, and the conclusions are solid, but there is a need for more reproducible data to address existing discrepancies and enhance its ...

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may ...